ORPHA:79481
Pemphigus foliaceus
Publications
3,508
89.6th percentile
Trials
6
Interventional, condition-specific
Researchers
962
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare superficial pemphigus disease characterized by multiple, pruritic, scaly, crusted cutaneous erosions, with flaky circumscribed patches, localized mostly on the face, scalp, trunk and extremities, often presenting an erythematous base. Mucosal involvement is rarely observed.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019324
- UMLS:C0263313
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,508 matched papers (1,594 in last 10 years) Source
- Phenotype characterisedPresent
20 HPO annotations (e.g. Autoimmunity; Abnormal blistering of the skin; Abnormal oral mucosa morphology) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
6 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
20
Associated phenotypes · MONDO:0019324
- Autoimmunity
- Abnormal blistering of the skin
- Abnormal oral mucosa morphology
- Neoplasm of the skin
- Crusting erythematous dermatitis
Showing 5 of 20 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0019324
- EFGARTIGIMOD ALFA·phase 3
- RILZABRUTINIB·phase 3
- ORILANOLIMAB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,508
3,508 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,508 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,594 in the last 10 years · high confidence · 89.6th percentile (publications denominator)
Phrase hits: 3,508 · MeSH hits: 0
Who's working on it?
962
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hashimoto T6 papers · 2026
Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Papers in Europe PMC - 02Schmidt E6 papers · 2026
Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
Papers in Europe PMC - 03
- 04Joly P5 papers · 2026
Department of Dermatology, Rouen University Hospital, Normandie University and INSERM U1234, European Reference Network for Rare Skin Diseases (ERN SKIN), Centre de Référence National des Maladies Bulleuses Auto-Immunes, Rouen, France.
Papers in Europe PMC - 05Abreu Velez AM4 papers · 2025
Georgia Dermatopathology Associates, Atlanta, GA, USA.
Papers in Europe PMC - 06Dmochowski M4 papers · 2026
Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 61701 Poznan, Poland.
Papers in Europe PMC - 07Tedbirt B4 papers · 2026
Department of Dermatology, Rouen University Hospital, Normandie University and INSERM U1234, European Reference Network for Rare Skin Diseases (ERN SKIN), Centre de Référence National des Maladies Bulleuses Auto-Immunes, Rouen, France.
Papers in Europe PMC - 08Abida O3 papers · 2026
"Autoimmunity, Cancer and Immunogenetics" research laboratory (LR18SP12), Immunology Department, Habib Bourguiba Hospital, University of Sfax, Sfax, 3029, Tunisia. olfaabida@yahoo.fr.
Papers in Europe PMC - 09Bahloul E3 papers · 2026
Dermatology Department, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Papers in Europe PMC - 10Bizikova P3 papers · 2025
College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; none in our sample are currently recruiting. 49 trials are registered for pemphigus, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
6 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.1th percentile).
high confidence · 90.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: pemphigus
49
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05898308·RECRUITING·Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
Not reviewed·Conditions: Pemphigus · Dermatologic Disease·Matched via name phrase
- NCT06454357·RECRUITING·A Clinical Study of B007 in the Treatment of Pemphigus.
Not reviewed·Conditions: Pemphigus·Matched via name phrase
- NCT06663943·NOT YET RECRUITING·A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Not reviewed·Conditions: Pemphigus Disease · Pemphigus Vulgaris (PV)·Matched via name phrase
- NCT07641725·RECRUITING·Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.
Not reviewed·Conditions: Oral Lesions in Patients With Pemphigus Vulgaris·Matched via name phrase
- NCT06904040·NOT YET RECRUITING·A Single-center Study of CM313 in Patients With Pemphigus
Not reviewed·Conditions: Pemphigus·Matched via name phrase
- NCT06971172·NOT YET RECRUITING·Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
Not reviewed·Conditions: Pemphigus Vulgaris·Matched via name phrase
- NCT04422912·RECRUITING·A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Not reviewed·Conditions: Pemphigus Vulgaris·Matched via name phrase
- NCT06581562·RECRUITING·Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Not reviewed·Conditions: Rheumatoid Arthritis · Pemphigus Vulgaris · Granulomatosis With Polyangiitis · Systemic Lupus Erythematosus·Matched via name phrase
- NCT06901427·NOT YET RECRUITING·Impact of a Lifestyle Program on Quality of Life in Pemphigus Patients
Not reviewed·Conditions: Pemphigus Disease·Matched via name phrase
- NCT07681388·RECRUITING·CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris
Not reviewed·Conditions: Pemphigus Vulgaris·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT02753777·RECRUITING·Autoimmune Blistering Diseases Study
Not reviewed·Conditions: Pemphigus Vulgaris · Pemphigus Foliaceus · Bullous Pemphigoid·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- ctis·2024-514886-21-00·Authorised, ongoing·Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corticosteroids) in pemphigus
- (RITUX 4)
skipped — LLM skipped (--skip-llm)
- ctis·2023-510297-14-00·Authorised, ongoing·Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pemphigus foliaceus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pemphigus foliaceus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pemphigus foliaceus"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pemphigus"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:28:45.699Z
